Abstract: A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-?-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.
Type:
Grant
Filed:
May 21, 2018
Date of Patent:
October 13, 2020
Assignee:
REDWOOD PHARMA AB
Inventors:
Clive H. Reading, Thomas Rowe, Mario G. Fsadni, Richard Coulon